Back to top
more

Veracyte (VCYT)

(Real Time Quote from BATS)

$38.05 USD

38.05
1,276,462

+1.46 (3.99%)

Updated Nov 7, 2024 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks News

Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 850% and 5.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket

Henry Schein's third-quarter results reflect an improvement in sales trends in Technology and Value-Added Services business.

ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket

Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.

Hologic (HOLX) Q4 Earnings Miss Estimates

Hologic (HOLX) delivered earnings and revenue surprises of -0.98% and 0.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket

IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.

CHE Misses on Q3 Earnings, Lowers '24 EPS View, Stock Up

Chemed's VITAS segment reports impressive revenue growth and margin expansion for the third quarter of 2024.

Paragon 28, Inc. (FNA) Stock Jumps 7.2%: Will It Continue to Soar?

Paragon 28, Inc. (FNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls

ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery.

EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls

Edwards Lifesciences reports strong contributions from all of the product groups - TAVR, TTMT and surgical structural heart - in the third quarter of 2024.

LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains

Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.

DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up

Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.

WBA Stock Up on Q4 Earnings & Revenues Beat, Unveils Strategic Action

Walgreens reports better-than-expected earnings and revenues in the fourth quarter of fiscal 2024.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening

Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Urmimala Biswas headshot

3 MedTech Stocks to Buy as Monetary Policy Eases

Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte

Intuitive Surgical, Masimo and Veracyte have been highlighted in this Industry Outlook article

Urmimala Biswas headshot

3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost

ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.